Chidamide reprograms AML-associated macrophages via HDAC3 inhibition to boost CD8+ T cell immunity

Acute myeloid leukemia (AML) is a highly aggressive hematological malignancy frequently associated with relapse and therapeutic resistance. AML‑associated macrophages (AAMs) within the microenvironment play an important role in immune escape. Chidamide, a histone deacetylase (HDAC) inhibitor, has been reported to activate CD8 + T cells to exert anti-tumor effects. However, its effect on AAMs remains unclear. The present study aimed to investigate the effects of chidamide on AAMs and the underlying mechanisms. Chidamide treatment conferred an immunologically activated phenotype on AAMs, characterized by upregulated expression of antigen‑presenting molecules, pro‑inflammatory cytokines, and chemokines. Moreover, chidamide reversed the suppressive effect of AAMs on the proliferation of co‑cultured CD8⁺ T cells. In vivo, chidamide treatment significantly decreased leukemia burden and polarized AAMs towards the M1 phenotype. Mechanistically, chidamide inhibited HDAC3, leading to enhanced H3K27 acetylation. Integrated multi‑omics analysis of RNA‑seq, ATAC‑seq, and CUT&Tag‑seq revealed that chidamide upregulated FOSL2 expression, which in turn activated the TNF‑α/NF‑κB signaling pathway. FOSL2 was found to directly bind to the TNF promoter, thereby driving TNF‑α/NF‑κB activation. Collectively, our findings demonstrate that chidamide reprograms immunosuppressive AAMs into an immunologically activated phenotype via selective HDAC3 inhibition, thereby eliciting anti-leukemic activity. These findings provide a novel mechanistic rationale for chidamide-based therapy in AML.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-20
DOI
https://doi.org/10.21203/rs.3.rs-11589394/v1
Primary Topic
Immune cells in cancer
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Chidamide reprograms AML-associated macrophages via HDAC3 inhibition to boost CD8+ T cell immunity

Yujie Zhang, Ziyi Liang, Rui Huang, Zhili Tan et al.
3 links
Research Square
Immune cells in cancer
preprint

Chidamide reprograms AML-associated macrophages via HDAC3 inhibition to boost CD8+ T cell immunity

Yujie Zhang, Ziyi Liang, Rui Huang, Zhili Tan, Yuhua Li, Xiaoning Li, Yaling Zheng
preprint en

Abstract

Acute myeloid leukemia (AML) is a highly aggressive hematological malignancy frequently associated with relapse and therapeutic resistance. AML‑associated macrophages (AAMs) within the microenvironment play an important role in immune escape. Chidamide, a histone deacetylase (HDAC) inhibitor, has been reported to activate CD8 + T cells to exert anti-tumor effects. However, its effect on AAMs remains unclear. The present study aimed to investigate the effects of chidamide on AAMs and the underlying mechanisms. Chidamide treatment conferred an immunologically activated phenotype on AAMs, characterized by upregulated expression of antigen‑presenting molecules, pro‑inflammatory cytokines, and chemokines. Moreover, chidamide reversed the suppressive effect of AAMs on the proliferation of co‑cultured CD8⁺ T cells. In vivo, chidamide treatment significantly decreased leukemia burden and polarized AAMs towards the M1 phenotype. Mechanistically, chidamide inhibited HDAC3, leading to enhanced H3K27 acetylation. Integrated multi‑omics analysis of RNA‑seq, ATAC‑seq, and CUT&Tag‑seq revealed that chidamide upregulated FOSL2 expression, which in turn activated the TNF‑α/NF‑κB signaling pathway. FOSL2 was found to directly bind to the TNF promoter, thereby driving TNF‑α/NF‑κB activation. Collectively, our findings demonstrate that chidamide reprograms immunosuppressive AAMs into an immunologically activated phenotype via selective HDAC3 inhibition, thereby eliciting anti-leukemic activity. These findings provide a novel mechanistic rationale for chidamide-based therapy in AML.

Research Square
Southern Medical University (CN)
National Natural Science Foundation of China
Good health and well-being
Immune cells in cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Chidamide reprograms AML-associated macrophages via HDAC3 inhibition to boost CD8+ T cell immunity — Yujie Zhang, Ziyi Liang, et al. · Research Square (2026) | TGRS Research Map | TGRS